SLN (Silence Therapeutics) Insider Ownership: 44.65 % (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLN Silence Therapeutics PLC SLN
46 GF Score
Price $11.94
GF Value $0.40
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics Insider Ownership?

Silence Therapeutics SLN +1.96% 46 Insider Ownership is 44.65 % as of Aug. 09, 2026. GuruFocus rates SLN with a GF Score™ of 46/100 and a GF Value™ of $0.40 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Silence Therapeutics's insider ownership is 44.65%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Silence Therapeutics's Institutional Ownership is 42.15%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Silence Therapeutics's Float Percentage Of Total Shares Outstanding is 75.58%.

Silence Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Silence Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Insider Ownership Chart

Silence Therapeutics Historical Data

The historical data trend for Silence Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 44.65 44.65 44.65 44.65 44.65 44.65 44.65 44.65 44.65 44.65
SLN
46GF Score
Silence Therapeutics PLC SLN
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silence Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 44.65 % mean?
Silence Therapeutics (SLN) has a Insider Ownership of 44.65 % as of Aug. 09, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Silence Therapeutics and its competitors.
Is Silence Therapeutics' Insider Ownership too high?
Silence Therapeutics' current Insider Ownership is 44.65 %. Overall, Silence Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Insider Ownership compare to NAUT and CHRS?
Silence Therapeutics' Insider Ownership of 44.65 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Silence Therapeutics and its competitors. Silence Therapeutics's current Insider Ownership is 44.65 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.40, compared to a current price of $11.94 — trading 2885% above its estimated fair value. The current Insider Ownership is 44.65 %. Silence Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Insider Ownership is 44.65 % as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $11.94 is trading 2885% above its estimated GF Value™ of $0.40. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Insider Ownership: 44.65 %
  • GF Value™: $0.40 vs. price of $11.94 (2885% above fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
46GF Score

Get the complete analysis for SLN

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.94
Price
$0.40
GF Value